NFKB1 and B-cell chronic lymphocytic leukemia: The Hsp90 inhibitor, NVP-AUY922-AG decreased transcription of NFkB target genes, and this effect was maintained for synergistic dual treatment with 2-FaraA of primary CLL cells [58].